Skip to main content

Achaogen Stock Forecast, Price & News

0.00 (0.00 %)
(As of 05/12/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume117,624 shs
Average Volume214,242 shs
Market Capitalization$1.06 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AKAOQ News and Ratings via Email

Sign-up to receive the latest news and ratings for Achaogen and its competitors with MarketBeat's FREE daily newsletter.

Achaogen logo

About Achaogen

Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. On April 15, 2019, Achaogen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on May 29, 2020.


News for Achaogen Inc
News for Achaogen Inc
December 30, 2020 |
Achaogen Inc - Ordinary Shares (AKAOQ)
Achaogen Inc - Ordinary Shares (AKAOQ)
August 17, 2020 |
Achaogen Inc.
Achaogen Inc.
June 10, 2020 |
AKAOQ Achaogen Inc - Ordinary Shares
AKAOQ Achaogen Inc - Ordinary Shares
April 22, 2020 |
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Year FoundedN/A

Sales & Book Value

Annual Sales$8.73 million





Market Cap$1.06 million
Next Earnings DateN/A


Overall MarketRank

0.64 out of 5 stars

Medical Sector

1351st out of 2,042 stocks

Pharmaceutical Preparations Industry

583rd out of 770 stocks

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Achaogen (OTCMKTS:AKAOQ) Frequently Asked Questions

What stocks does MarketBeat like better than Achaogen?

Wall Street analysts have given Achaogen a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Achaogen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Achaogen's stock price been impacted by COVID-19 (Coronavirus)?

Achaogen's stock was trading at $0.0105 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AKAOQ stock has increased by 109.5% and is now trading at $0.0220.
View which stocks have been most impacted by COVID-19

Who are Achaogen's key executives?

Achaogen's management team includes the following people:
  • Mr. Gary H. Loeb, Consultant (Age 51, Pay $458k)
  • Ms. Jeannie Lloyds, VP of Sales
  • Ms. Elizabeth P. Bhatt, Consultant (Age 53)
  • Mr. Nicholas K. Campbell, Chief Restructuring Officer

Who are some of Achaogen's key competitors?

What is Achaogen's stock symbol?

Achaogen trades on the OTCMKTS under the ticker symbol "AKAOQ."

How do I buy shares of Achaogen?

Shares of AKAOQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Achaogen's stock price today?

One share of AKAOQ stock can currently be purchased for approximately $0.02.

How much money does Achaogen make?

Achaogen has a market capitalization of $1.06 million and generates $8.73 million in revenue each year.

How many employees does Achaogen have?

Achaogen employs 42 workers across the globe.

What is Achaogen's official website?

The official website for Achaogen is

Where are Achaogen's headquarters?

Achaogen is headquartered at 1 TOWER PLACE SUITE 300, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Achaogen?

Achaogen's mailing address is 1 TOWER PLACE SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-800-3636 or via email at [email protected]

This page was last updated on 5/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.